NCI-CONNECT Rare Brain & Spine Tumor Network
 

Referrals

Nurses and doctors in the clinic
Credit: NCI-CONNECT Staff

The diagnosis of a rare brain or spinal cord tumor can be overwhelming and patients may feel it is urgent to get started with their care. Patients are encouraged to seek a second opinion for care and treatment options from a doctor who has experience treating their brain or spine tumor.

The NCI Neuro-Oncology Branch at the NIH in Bethesda, Maryland, has doctors and nurses with extensive experience treating rare brain and spinal cord tumors. Patients can visit our Neuro-Oncology Branch Brain Tumor Clinic at the NIH for an evaluation or consultation with our healthcare providers. Consultations for patients with rare brain and spine tumors are free-of-charge.

Our Neuro-Oncology Branch healthcare team provides patients with a comprehensive care plan that, together with their physician at home, will ensure they get the best treatment possible.

Referral Information

To make an appointment or refer a patient, contact:

NCINOBReferrals@mail.nih.gov or call 1-866-251-9686 or 240-760-6010 

(Monday to Friday, 9:00 a.m.–5:00 p.m. ET)

Our patient care support team will coordinate all NIH appointments and travel.

Patients referred to the NIH will have the option to participate in a clinical trial at the NCI or at a Brain Tumor Trials Collaborative (BTTC) center. The BTTC is a network of renowned medical centers throughout the United States that works with NCI-CONNECT to provide clinical trials to patients with rare CNS tumors. This allows patients to access cutting-edge therapies at a center closer to their home.

  • Posted: September 17, 2018

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Referrals was originally published by the National Cancer Institute.”

We welcome your comments on this post. All comments must follow our comment policy.